Cargando…

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy

Spinal muscular atrophy (SMA), a leading genetic cause of infant death, is a neurodegenerative disease characterized by the selective loss of particular groups of motor neurons (MNs) in the anterior horn of the spinal cord with progressive muscle wasting. SMA is caused by a deficiency of the surviva...

Descripción completa

Detalles Bibliográficos
Autor principal:	Chen, Tai-Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Therapeutic Perspectives in Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768327/ https://www.ncbi.nlm.nih.gov/pubmed/33488772 http://dx.doi.org/10.1177/1756286420979954

Ejemplares similares

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Autophagy inhibition: a new therapeutic target in spinal muscular atrophy
por: Piras, Antonio, et al.
Publicado: (2018)

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
por: Giorgia, Querin, et al.
Publicado: (2023)

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
por: Millere, Elina, et al.
Publicado: (2021)

Multifaceted roles of microRNAs: From motor neuron generation in embryos to degeneration in spinal muscular atrophy
por: Chen, Tai-Heng, et al.
Publicado: (2019)

Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy
por: Fan, Baoyan, et al.
Publicado: (2020)

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
por: Kariyawasam, Didu S. T., et al.
Publicado: (2019)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
por: Trifunov, Selena, et al.
Publicado: (2020)

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
por: Savini, Giovanni, et al.
Publicado: (2021)

Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis
por: He, Jimin, et al.
Publicado: (2021)

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients
por: Magen, Iddo, et al.
Publicado: (2022)

An Overview of MicroRNAs as Biomarkers of ALS
por: Joilin, Greig, et al.
Publicado: (2019)

Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
por: Leon-Astudillo, Carmen, et al.
Publicado: (2022)

Circulating microRNAs in Symptomatic and Asymptomatic Carotid Stenosis
por: Grosse, Gerrit M., et al.
Publicado: (2021)

Circulating microRNAs as Biomarkers, Therapeutic Targets, and Signaling Molecules
por: Ajit, Seena K.
Publicado: (2012)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies
por: Piga, Daniela, et al.
Publicado: (2019)

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
por: Sleigh, James N., et al.
Publicado: (2011)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

Corrigendum: An Overview of MicroRNAs as Biomarkers of ALS
por: Joilin, Greig, et al.
Publicado: (2019)

Expression of Human Endogenous Retrovirus-K in Spinal and Bulbar Muscular Atrophy
por: Rex, Cody, et al.
Publicado: (2019)

Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy
por: Ramos-Platt, Leigh, et al.
Publicado: (2022)

Exosomal microRNAs as Potential Biomarkers and Therapeutic Agents for Acute Ischemic Stroke: New Expectations
por: Xu, Yingzhi, et al.
Publicado: (2022)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

MicroRNAs and Their Targetomes in Tumor-Immune Communication
por: Cho, Sunglim, et al.
Publicado: (2020)

GEMINs: potential therapeutic targets for spinal muscular atrophy?
por: Borg, Rebecca, et al.
Publicado: (2014)

Correlation Between Maximal Tongue Pressure and Swallowing Function in Spinal and Bulbar Muscular Atrophy
por: Gwak, Dae-Won, et al.
Publicado: (2021)

Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
por: Kotulska, Katarzyna, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Sociodemographic and clinical characteristics and access to health care in patients with spinal muscular atrophy in Argentina
por: Vazquez, Gabriel Adolfo, et al.
Publicado: (2023)

Extracellular Vesicle Proteins and MicroRNAs as Biomarkers for Traumatic Brain Injury
por: Guedes, Vivian A., et al.
Publicado: (2020)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

MicroRNA-based targeting of the Rho/ROCK pathway in therapeutic strategies after spinal cord injury
por: Kimura, Tetsu, et al.
Publicado: (2022)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Spinal Muscular Atrophy and Communicating Hydrocephalus: A Novel or a Well-Established Rare Association?
por: Alkhars, Fatimah Z, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tj0sv8rp58jvme91l4gj6gtm1k